ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2025
Antibiofilm activity of silver nanoparticles against Candida sp. isolated from the oral cavity.
Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida biofilm is difficult to control due to the poor penetration and unspecificity of antifungal drugs against the microorganisms associated with this structure. Nanoparticles have been investigated for their antimicrobial potential. In this context, the present study evaluated the antibiofilm activity of silver nanoparticle colloids (AgNPs) against candida isolated from the oral cavity. AgNPs were prepared in two different ethanolic syntheses - without and with ammonium hydroxide: AgNP-1 and AgNP-2, respectively. AgNPs were characterized by atomic absorption spectroscopy (AAS), UV-visible (UV-vis) absorption electron spectroscopy, zeta potential, dynamic light scattering (DLS), and transmission electron microscopy (TEM). Subsequently, they were evaluated against biofilm formation by clinical isolates of Candida albicans and Candida krusei by determining the minimum inhibitory concentration (MIC), minimum fungicidal concentration (MFC), and minimum biofilm formation inhibitory concentration (MBIC50). AgNPs inhibited biofilm formation of tested C. albicans and C. krusei and showed antibiofilm activity at subinhibitory concentrations against all yeasts. AgNP-1 inhibited biofilm formation at concentrations between 7.55 and 60.46 µg/mL and AgNP-2 between 7.71 and 30.80 µg/mL. The characterization of AgNP showed that AgNP-1 and AgNP-2 differ mainly in size and dispersion, with AgNP-2 being monodisperse, indicating that these characteristics could be related to the activity against the formation of C. albicans and C. krusei biofilm, and the silver nanoparticles may represent innovative and complementary alternatives to the available antifungal arsenal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.